Beth Marsh will lead commercialization for Neurotech, which gained FDA approval for its eye disease therapy. Neurotech in May ...

The global marketplace is here to stay. But global competition must take place on fair, transparent and enforceable terms, ...

Find out how you can mitigate risks when expanding your biotech business internationally in the current tariff and trade ...

Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted ...

Zurich-based startup Veraxa Biotech has reached a deal to merge with special purpose acquisition company (SPAC) Voyager, ...

Thermo Fisher Scientific reported better-than-expected profit and revenue for the first quarter on Wednesday, helped by ...

Biotech entrepreneur Sam Waksal has been accused of "reckless conduct," including using a veterinary medicine on a severely ...

Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...

Switzerland's Xlife Sciences AG said on Wednesday its portfolio company, VERAXA Biotech AG, will merge with Voyager Acquisition in a deal that will value the combined company at $1.64 billion.

GenScript Biotech Corporation, a global leader in biotechnology research services, and NSG Bio, Singapore's premier biotech ...